Here are six key points:
1. SeaSpine’s revenue hit $34.2 million for the second quarter, a 3 percent year over year increase. U.S. revenue was up 1.1 percent to $30.4 million, driven by $16 million in U.S. orthobiologics revenue. The U.S. spinal instrumentation revenue hit $14.4 million.
2. International revenue jumped 20.5 percent year over year to $3.8 million.
3. During the second quarter, SeaSpine launched the Mariner Posterior Fixation System, a modular pedicle screw system used during posterior lumbar fixation, and the limited commercial launch of Skipjack Expandable Interbody System, designed to provide in-situ expansion for height or lordosis.
4. Net loss reached $8 million, less than $12 million reported for the second quarter last year. Operating expenses reached $28.4 million, down from $31.5 million due to lower selling, general and administration as well as intangible amortization expenses.
5. The company reported $12.3 million cash on hand and $4 million of outstanding borrowing against a $30 million credit facility.
6. SeaSpine expects full year revenue to reach $130 million to $133 million, a 1 percent to 3 percent growth over 2016.
More articles on orthopedic devices:
Stryker names new board member: 4 insights
LongueVue Capital acquires Zavation Medical Products: 5 insights
Smith & Nephew, Zimmer Biomet, NuVasive & more: 13 device company key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
